Watertown, United States
Vigil Neuroscience is a clinical-stage biotechnology company established in 2020 with a focus on developing treatments for neurodegenerative diseases. The company's slogan, "Harnessing the power of microglia to transform treatments for neurodegenerative diseases," underlines its innovative approach. Vigil Neuroscience aims to restore the vigilance of microglia, the sentinel immune cells of the brain, by utilizing modern neuroscience drug development tools.
The company's lead clinical candidate, VGL101, holds promise as a fully human monoclonal antibody agonist targeting the human triggering receptor expressed on myeloid cells 2 (TREM2) for the treatment of the rare and fatal neurodegenerative disease adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Additionally, Vigil Neuroscience is developing VG-3927, a novel small molecule TREM2 agonist primarily focused on addressing Alzheimer’s disease (AD) in genetically defined subpopulations.
The company's commitment to addressing both rare and common neurodegenerative diseases through precision-based therapies reflects a potential for significant impact on patient outcomes and their families. Notably, Vigil Neuroscience secured a $40.00M post-IPO equity investment on 27 June 2024 from Sanofi. This strategic investment underlines the confidence of established players in the biotechnology and healthcare sectors in Vigil Neuroscience's approach and potential for success.
As Vigil Neuroscience continues to advance its research and development efforts, its innovative approach and promising pipeline position it as a company to watch in the biotechnology and healthcare sectors.
